Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Gastrointestinal Cancers
•
Medical Oncology
How would you manage oligometastatic colon cancer with a resected primary and liver metastasis found to be MSI-H?
Would you prioritize chemotherapy or immunotherapy for curative intent treatment?
Related Questions
Do you modify the dose of Naliri in Nalirifox for patient that are heterozygous for UGT1A1 mutations?
What systemic therapy and dose adjustments would you implement for patients with pancreas cancer and cirrhosis with pancytopenia?
How does the presence of CNS disease affect your choice of first line therapy in Her2+ gastric adenocarcinoma?
How would you approach a case of enteroblastic cholangiocarcinoma?
After neoadjuvant Nivolumab/Ipilimumab x4, do you offer adjuvant Nivolumab in the adjuvant setting for oligometastatic MSI-high colon cancer in a patient who achieved CR?
Would you offer adjuvant therapy for resected GB cancer > 6 months of surgery time if there are high risk features (pT3N0, positive margins, + PNI) and therapy was delayed due to hepatic abscess post operative?
How do you manage oxaliplatin-induced splenomegaly?
Is there a role of adjuvant or systemic therapy for patients with resected stage I colon cancer with subsequent local recurrence S/P a second resection and now has NED?
What adjuvant treatment would you give to a locally advanced esophageal adenocarcinoma status post neoadjuvant FLOT s/p resection with positive margins?
How would you approach unexpected chemo breaks during planned neoadjuvant chemoradiation for esophageal adenocarcinoma?